11 Results for "

metabolic parameters

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "metabolic parameters" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-N4170
CAS No.: 23725-05-5
Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N9447
CAS No.: 79595-97-4
Norbergenin is a polyphenolic isocoumarin derivative. Norbergenin acts as a non-competitive inhibitor of bovine adrenal tyrosine hydroxylase (TH) with a Ki value of 69.6 μM. Norbergenin inhibits lipopolysaccharide-induced inflammatory responses in macrophages by suppressing the activation of NF-κB, MAPK and STAT3, as well as blocking metabolic reprogramming . Norbergenin inhibits aluminum chloride-induced oxidative stress and apoptosis and restores neurocognitive parameters. Norbergenin scavenges ROS through multiple mechanisms and protects cell membranes from lipid peroxidation damage. Norbergenin can be used in research related to Alzheimer's disease, peptic ulcer and arthritis .
loading...
    loading...
Cat. No.: HY-113353
CAS No.: 583-08-4
Purity:  99.93%
Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease [1]
loading...
    loading...
Cat. No.: HY-117912
CAS No.: 1431553-15-9
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
loading...
    loading...
Cat. No.: HY-113353S
CAS No.: 1216737-36-8
Purity:  99.07%
Nicotinuric acid-d4 is the 4-labeled Nicotinuric acid (HY-113353). Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease [1]
loading...
    loading...
Cat. No.: HY-113353R
CAS No.: 583-08-4
Nicotinuric acid (Standard) is the analytical standard of Nicotinuric acid (HY-113353). This product is intended for research and analytical applications. Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease [1]
loading...
    loading...
Cat. No.: HY-174425
CAS No.: 3077254-39-5
Target:  

Cytochrome P450

Research Areas:  

Cancer

CYP1B1-IN-9 is a highly selective and competitive CYP1B1 Inhibitor with IC50 values of 1.48 nM, > 100 μM, and > 80 μM for CYP1B1, CYP1A1, and CYP1A2, respectively. CYP1B1-IN-9 significantly inhibits the migration and invasion of A549/T cells. CYP1B1-IN-9 has the ability to resensitize Paclitaxel (HY-B0015)-resistant cells, and good metabolic stability and safety, and shows favorable pharmacokinetic parameters. CYP1B1-IN-9 can be used for the study of tumor-drug resistance .
loading...
    loading...
Cat. No.: HY-P11830
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
loading...
    loading...
Cat. No.: HY-N4170R
CAS No.: 23725-05-5
Chebulic acid (Standard) is the analytical standard of Chebulic acid (HY-N4170). This product is intended for research and analytical applications. Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection .
loading...
    loading...
Cat. No.: HY-181709
Synonyms: TG062
TPM003 (TG062) is a triple agonist of GLP-1R, GIPR and GCGR, with EC50 values of 33.9, 12.5 and 92.9 pM, respectively. TPM003 suppresses appetite, regulates blood glucose, enhances insulin sensitivity, reduces gastrointestinal intolerance, promotes hepatic lipid mobilization and increases energy expenditure. TPM003 induces weight loss, improves metabolic parameters, reverses hepatic steatosis and optimizes liver function markers. TPM003 is applicable for research on obesity and non-alcoholic steatohepatitis .
loading...
    loading...
Cat. No.: HY-L920
24,816 compounds
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.
  • 1